GLPwatch
Allergic Reaction to Exenatide and Lixisenatide but Not to Liraglutide: Unveiling Anaphylaxis to Glucagon-Like Peptide 1 Receptor Agonists.
Diabetes Care · 2019
Last updated 2026-07-16| Journal | Diabetes Care, 2019 |
|---|---|
| Citations | 16 |
| Relative citation ratio | 0.81 |
| NIH percentile | 43 |
| Molecules | liraglutide, exenatide, lixisenatide |
Full record and abstract on PubMed 31296642 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.